Stock COEGIN COEGIN PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Coegin Pharma AB

Equities

COEGIN

SE0020357754

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
3.01 SEK +3.79% Intraday chart for Coegin Pharma AB -0.33% -44.10%
2023 Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 227.5 96.51
Enterprise Value (EV) 1 201.9 92.69
P/E ratio -8.52 x -2.71 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -7.8 x -2.9 x
EV / FCF -17,087,361 x -4,727,664 x
FCF Yield -0% -0%
Price to Book 12.1 x 4.59 x
Nbr of stocks (in thousands) 6,117 6,943
Reference price 2 37.20 13.90
Announcement Date 4/28/22 5/4/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales - - -
EBITDA 1 -46.25 -25.88 -31.97
EBIT 1 -46.28 -25.88 -34.69
Operating Margin - - -
Earnings before Tax (EBT) 1 -46.24 -25.85 -35.24
Net income 1 -46.24 -25.85 -35.24
Net margin - - -
EPS 2 -35.39 -4.368 -5.139
Free Cash Flow - -11.81 -19.61
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 4/28/22 4/28/22 5/4/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt 1 - - -
Net Cash position 1 16.6 25.7 3.82
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -11.8 -19.6
ROE (net income / shareholders' equity) - -136% -172%
ROA (Net income/ Total Assets) - -63.7% -72.8%
Assets 1 - 40.57 48.42
Book Value Per Share 2 12.80 3.080 3.030
Cash Flow per Share 2 12.70 3.700 0.5500
Capex - - -
Capex / Sales - - -
Announcement Date 4/28/22 4/28/22 5/4/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
COEGIN PHARMA AB Stock Coegin Pharma AB
-44.10% 4.45M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. COEGIN Stock
  4. Financials Coegin Pharma AB